126 related articles for article (PubMed ID: 37821725)
1. Moving out of CF
Witoszka K; Matalińska J; Misicka A; Lipiński PFJ
ChemMedChem; 2023 Dec; 18(23):e202300315. PubMed ID: 37821725
[TBL] [Abstract][Full Text] [Related]
2. In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.
Matalińska J; Lipiński PFJ; Kosson P; Kosińska K; Misicka A
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086743
[TBL] [Abstract][Full Text] [Related]
3. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
Lelas S; Li YW; Wallace-Boone TL; Taber MT; Newton AE; Pieschl RL; Davis CD; Molski TF; Newberry KS; Parker MF; Gillman KW; Bronson JJ; Macor JE; Lodge NJ
Neuropharmacology; 2013 Oct; 73():232-40. PubMed ID: 23770339
[TBL] [Abstract][Full Text] [Related]
4. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
5. Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography.
Chen S; Lu M; Liu D; Yang L; Yi C; Ma L; Zhang H; Liu Q; Frimurer TM; Wang MW; Schwartz TW; Stevens RC; Wu B; Wüthrich K; Zhao Q
Nat Commun; 2019 Feb; 10(1):638. PubMed ID: 30733446
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists.
Schöppe J; Ehrenmann J; Klenk C; Rucktooa P; Schütz M; Doré AS; Plückthun A
Nat Commun; 2019 Jan; 10(1):17. PubMed ID: 30604743
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the human NK
Yin J; Chapman K; Clark LD; Shao Z; Borek D; Xu Q; Wang J; Rosenbaum DM
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13264-13269. PubMed ID: 30538204
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and [3,3]-sigmatropic rearrangements of 5-(pentafluorosulfanyl)-pent-3-en-2-ol, its homologues, and trifluoromethyl analogues.
Dudziński P; Husstedt WS; Matsnev AV; Thrasher JS; Haufe G
Org Biomol Chem; 2021 Jun; 19(25):5607-5623. PubMed ID: 34100055
[TBL] [Abstract][Full Text] [Related]
9. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
11. Docking is not enough: 17-trifluoromethylphenyl trinor PGF2α is only a very weak ligand of neurokinin-1 receptor.
Matalińska J; Lipiński PFJ
Exp Mol Pathol; 2023 Feb; 129():104849. PubMed ID: 36526011
[TBL] [Abstract][Full Text] [Related]
12. Novel NK1R-Targeted
Matalińska J; Kosińska K; Halik PK; Koźmiński P; Lipiński PFJ; Gniazdowska E; Misicka A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163139
[TBL] [Abstract][Full Text] [Related]
13. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract][Full Text] [Related]
14. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
[TBL] [Abstract][Full Text] [Related]
15. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Biological Evaluation of Aprepitant Based
Halik PK; Koźmiński P; Matalińska J; Lipiński PFJ; Misicka A; Gniazdowska E
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335981
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
18. Studies of Halogen Bonding Induced by Pentafluorosulfanyl Aryl Iodides: A Potential Group of Halogen Bond Donors in a Rational Drug Design.
Sumii Y; Sasaki K; Tsuzuki S; Shibata N
Molecules; 2019 Oct; 24(19):. PubMed ID: 31591340
[TBL] [Abstract][Full Text] [Related]
19. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of Phthalocyanines with a Pentafluorosulfanyl Substituent at Peripheral Positions.
Iida N; Tanaka K; Tokunaga E; Mori S; Saito N; Shibata N
ChemistryOpen; 2015 Dec; 4(6):698-702. PubMed ID: 27308194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
